Early transcatheter aortic valve replacement reduces cardiovascular events in asymptomatic aortic stenosis patients

New analysis from the EARLY TAVR trial showed patients between the age of 65 and 70 years old derived the most benefits of a strategy of early intervention with transcatheter aortic valve replacement (TAVR) compared to other age groups, especially in regards to stroke risk, and in regards to the composite of death, stroke, and heart failure hospitalization. The late-breaking results were presented today at the Society for Cardiovascular Angiography & Interventions (SCAI) 2025 Scientific Sessions.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup